Reality Check

MMIT Reality Check on Ulcerative Colitis (Aug 2019)

August 9, 2019

According to our recent payer coverage analysis for ulcerative colitis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for ulcerative colitis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for ulcerative colitis treatments shows that under the pharmacy benefit, about 62% and 58% of the lives under commercial and health exchange formularies are covered with utilization management restrictions, respectively.

Trends: In April 2019, Highmark Inc. said it is targeting autoimmune diseases under a new outcomes-based contract with Takeda Pharmaceuticals U.S.A., Inc. for Entyvio (vedolizumab).

MMIT Reality Check on Merkel Cell Carcinoma (Aug 2019)

August 2, 2019

According to our recent payer coverage analysis for Merkel cell carcinoma treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for Merkel cell carcinoma treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for Merkel cell carcinoma treatments shows that under the pharmacy benefit, about 27% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: In December 2018, the FDA gave accelerated approval to Keytruda (pembrolizumab) for use in adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.

MMIT Reality Check on Parkinson’s Disease (Jul 2019)

July 26, 2019

According to our recent payer coverage analysis for Parkinson’s disease treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for Parkinson’s disease treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for Parkinson’s disease treatments shows that under the pharmacy benefit, about 45% of the lives under commercial formularies are covered without utilization management restrictions.

Trends: Given the number of generic orals, management of the remaining name-brand oral products is restrictive but less so than in other classes. With many strong orals available, understanding how restrictions translate (or don’t) to brand-name products is critical.

MMIT Reality Check on Kidney Cancer (Jul 2019)

July 19, 2019

According to our recent payer coverage analysis for kidney cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for kidney cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for kidney cancer treatments shows that under the pharmacy benefit, about 58% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: Currently, Sutent leads the renal cell carcinoma market and may have bolstered its standing with 2017’s label expansion to include use in the adjuvant setting.

MMIT Reality Check on Bipolar Disorder (Jul 2019)

July 12, 2019

According to our recent payer coverage analysis for bipolar disorder treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for bipolar disorder treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for bipolar disorder treatments shows that under the pharmacy benefit, about 43% of the lives under commercial and Medicare formularies are covered with utilization management restrictions.

Trends: The market contains multiple strong oral generics. Competition amongest brand name products after failure of oral generics is expected.

MMIT Reality Check on Psoriatic Arthritis (Jul 2019)

July 5, 2019

According to our recent payer coverage analysis for psoriatic arthritis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for psoriatic arthritis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for psoriatic arthritis treatments shows that under the pharmacy benefit, about 74% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: Manufacturers with franchises across indications often hold contracting power and improved positio, which is everything in this market. In terms of contracting, Humira is the product to beat, and Enbrel battles for the second place.